# US 2020/0206226 A1 · Mpo inhibitors for use in medicine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206226 A1
- Document ID: US20200206226A1
- Status: Published application
- Kind: A1
- Application number: 16/631,548
- Filed: 2018-07-12
- Published: 2020-07-02
- Earliest claimed: 2017-07-17
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Andrew WHITTAKER; Hitesh Jayantilal SANGANEE
- Web page: https://patentgrep.com/patent/US20200206226A1

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 15/10: for impotence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to new therapeutic uses of MPO inhibitors and methods of treatment involving the same.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

A method of treatment or prophylaxis of male infertility in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a myeloperoxidase (MPO) inhibitor.

### Claim 16 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the patient is suffering from male idiopathic infertility.

### Claim 17 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the patient is a human patient.

### Claim 18 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the patient is a non-human land mammal.

### Claim 19 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the MPO inhibitor inhibits oxidative stress-induced sperm damage and/or prevents spermatozoa triggered NETosis.

### Claim 20 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the myeloperoxidase inhibitor is 1-(2-isopropoxyethyl)-2-thioxo-2,3-dihydro-1H-pyrrolo[3,2-d]pyrimidin-4(5H)-one, or a pharmaceutically acceptable salt or solvate thereof

### Claim 21 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the myeloperoxidase inhibitor is 3-[[(2R)-tetrahydrofuran-2-yl]methyl]-2-thioxo-7H-purin-6-one, or a pharmaceutically acceptable salt or solvate thereof

### Claim 22 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the myeloperoxidase inhibitor is a compound of formula (I)
wherein:
R1 is H, F, Cl or CF3;
R2 is H, CH3 or C2H5; and
R3 is H, CH3, C2H5, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl or cyclopentyl;
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 23 (depends on 15)

Method of treatment or prophylaxis according to claim 15, wherein the myeloperoxidase inhibitor is
or a pharmaceutically acceptable salt or solvate thereof.

### Claim 24

A kit comprising a pharmaceutical composition comprising a MPO inhibitor or a pharmaceutically acceptable salt or solvate thereof, and instructions to administer the pharmaceutical composition in a method of treatment or prophylaxis of male idiopathic infertility.

### Claim 25 (depends on 24)

Kit according to claim 24 wherein the MPO inhibitor is 1-(2-isopropoxyethyl)-2-thioxo-2,3-dihydro-1H-pyrrolo[3,2-d]pyrimidin-4(5H)-one, 3-[[(2R)-tetrahydrofuran-2-yl]methyl]-2-thioxo-7H-purin-6-one or a compound of formula (I)
wherein R1 is H, F, Cl or CF3; R2 is H, CH3 or C2H5; and R3 is H, CH3, C2H5, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, cyclopropylmethyl, cyclobutyl, cyclobutylmethyl or cyclopentyl, or a pharmaceutically acceptable salt or solvate thereof.
